

HENRY A. WAXMAN, CALIFORNIA  
CHAIRMAN

JOHN D. DINGELL, MICHIGAN  
CHAIRMAN EMERITUS  
EDWARD J. MARKEY, MASSACHUSETTS  
RICK BOUCHER, VIRGINIA  
FRANK PALLONE, JR., NEW JERSEY  
BART GORDON, TENNESSEE  
BOBBY L. RUSH, ILLINOIS  
ANNA G. ESHOO, CALIFORNIA  
BART STUPAK, MICHIGAN  
ELIOT L. ENGEL, NEW YORK  
GENE GREEN, TEXAS  
DIANA DEGETTE, COLORADO  
VICE CHAIRMAN  
LOIS CAPPS, CALIFORNIA  
MIKE DOYLE, PENNSYLVANIA  
JANE HARMAN, CALIFORNIA  
JAN SCHAKOWSKY, ILLINOIS  
CHARLES A. GONZALEZ, TEXAS  
JAY INSLEE, WASHINGTON  
TAMMY BALDWIN, WISCONSIN  
MIKE ROSS, ARKANSAS  
ANTHONY D. WEINER, NEW YORK  
JIM MATHESON, UTAH  
G.K. BUTTERFIELD, NORTH CAROLINA  
CHARLIE MELANCON, LOUISIANA  
JOHN BARROW, GEORGIA  
BARON P. HILL, INDIANA  
DORIS O. MATSUI, CALIFORNIA  
DONNA CHRISTENSEN, VIRGIN ISLANDS  
KATHY CASTOR, FLORIDA  
JOHN SARBANES, MARYLAND  
CHRISTOPHER MURPHY, CONNECTICUT  
ZACHARY T. SPACE, OHIO  
JERRY McNERNEY, CALIFORNIA  
BETTY SUTTON, OHIO  
BRUCE BRALEY, IOWA  
PETER WELCH, VERMONT

JOE BARTON, TEXAS  
RANKING MEMBER

ROY BLUNT, MISSOURI  
DEPUTY RANKING MEMBER  
RALPH M. HALL, TEXAS  
FRED UPTON, MICHIGAN  
CLIFF STEARNS, FLORIDA  
ED WHITFIELD, KENTUCKY  
JOHN SHIMKUS, ILLINOIS  
JOHN B. SHADEGG, ARIZONA  
STEVE BUYER, INDIANA  
GEORGE RADANOVICH, CALIFORNIA  
JOSEPH R. PITTS, PENNSYLVANIA  
MARY BONO MACK, CALIFORNIA  
LEE TERRY, NEBRASKA  
MIKE ROGERS, MICHIGAN  
SUE WILKINS MYRICK, NORTH CAROLINA  
JOHN SULLIVAN, OKLAHOMA  
TIM MURPHY, PENNSYLVANIA  
MICHAEL C. BURGESS, TEXAS  
MARSHA BLACKBURN, TENNESSEE  
PHIL GINGREY, GEORGIA  
STEVE SCALISE, LOUISIANA  
PARKER GRIFFITH, ALABAMA  
ROBERT E. LATTA, OHIO

ONE HUNDRED ELEVENTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

MAJORITY (202) 225-2927  
FACSIMILE (202) 225-2525  
MINORITY (202) 225-3641

energycommerce.house.gov

May 19, 2010

Mr. James Plante  
Chief Executive Officer  
Pathway Genomics Corporation  
4045 Sorrento Valley Blvd.  
San Diego, CA 92121

Dear Mr. Plante:

The Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are examining personal genetic tests sold to consumers over the Internet. Recent press reports suggest that your company is now seeking to sell these tests in retail locations, despite concern from the scientific community regarding the accuracy of test results.<sup>1</sup>

In order to assist the Committee with its examination of this issue, we ask that you provide the Committee with the following information and documents for the period from January 1, 2007, to the present:

1. A chart listing the conditions, diseases, consumer drug responses, and adverse reactions for which you test;

---

<sup>1</sup> *Start-Up May Sell Genetic Tests in Stores*, The New York Times (May 10, 2010); *Walgreens Delays Selling Genetic Testing Kit*, The New York Times (May 13, 2010).


2. All policy documents, training materials, or written guidance materials regarding genetic counseling and physician consultations, including documents regarding what conditions, diseases, drug responses, or adverse reactions trigger the need for genetic counseling or physician consultation, and documents governing communications with consumers regarding individual genetic testing results;
3. All documents relating to the ability of your genetic testing products to accurately identify consumer risk, including:
  - a. internal and external communications regarding the accuracy of your testing;
  - b. documents describing how your analysis of individual test results controls for scientific factors such as age, race, gender, and geographic location;
  - c. third party communications validating the association between the scientific data your company uses for analyzing test results and the consumer's risk for each condition, disease, drug response, or adverse reaction as identified by the results of an individual test; and
  - d. documents relating to proficiency testing conducted by your clinical laboratories.
4. All documents regarding your policies for processing and use of individual DNA samples collected from consumers, including:
  - a. policy documents and protocols regarding collection, storage, and processing of individual DNA samples;
  - b. policy documents and protocols relating to protection of consumer privacy; and
  - c. documents regarding collected DNA sample uses other than to provide individual genetic counseling to a consumer, including documents relating to third-party use of collected DNA samples.
5. All documents regarding compliance with the Federal Food, Drug, and Cosmetic Act and U.S. Food and Drug Administration (FDA) regulations.

Mr. James Plante  
May 19, 2010  
Page 3


Please produce the requested information by June 4, 2010. Please include the requested information for all units, divisions, affiliates, or subsidiaries controlled or owned in whole or in part by your company.

An attachment to this letter provides additional information on how to respond to the Committee's request. If you have questions regarding this request, please contact Tiffany Benjamin of the Committee staff at (202) 226-2424. The Republican staff contact, Alan Slobodin, may be reached at (202) 225-3641.

Sincerely,




Henry A. Waxman  
Chairman



Bart Stupak  
Chairman  
Subcommittee on Oversight  
and Investigations



Joe Barton  
Ranking Member



Michael C. Burgess  
Ranking Member  
Subcommittee on Oversight  
and Investigations

Enclosure